In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Immuno-Oncology: Halfway To Adulthood

Almost a decade on since the first approval for an immuno-oncology therapy, In Vivo analyzes the current landscape, the evolution of combination cancer treatments that use the immune system to target disease and future commercial potential for the market.

ImmunoOncology Cancer BioPharmaceutical

Building Bayer For The Next Decade And Navigating A Patent Cliff

As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.

C-Suite Speaks Leadership Strategy

Investment Outlook For Cell And Gene Therapies Is Cautiously Optimistic

Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.

Regenerative Medicine Financing Gene Therapy

Podcast: Innovations In Market Access

In Vivo welcomes Indranil Bagchi, SVP of global value and access at Novartis Oncology, and Srikant Vaidyanathan, senior partner and managing director of the Boston Consulting Group, onto the podcast to discuss the future of market access as a function in the biopharma industry.   


Market Access Reimbursement Strategy

Recent Tweets from In Vivo

CPhI North America Preview

The CphI North America Preview eBook is live! Click here and discover 8 articles with topics that include clinical trials, biosimilars and much more.

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Medtech Innovators Must Find The Right Problems To Solve

In the world of medtech innovation, investment and market access, commentators are seeing a maturing attitude to risk, more readiness to address workflows and greater awareness of being on the ball in a regulatory sense. Senior executives from consultancy firm Technology Commercialization Group (TCG) give In Vivo their take on what is behind these changes.

Business Strategies Growth

Deal Of The Year 2018 Winners Announced

Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are...

Deals Growth

Does It Grow On Trees? 2018 VC Financing Trends

Last year saw some serious early-stage funding, major later stage financings and more cash filtering into seed rounds. Follow the timeline of venture capital transactions throughout 2018 worth more than $100m. A record-breaking year for biotech financing. 

Financing Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

BlueRock Therapeutics: Sizing Up The Regenerative Power Of Cells

Bayer's novel 2016 joint venture with the venture capital group Versant Ventures has spawned something like a big pharma, new science start-up, with an open mandate to disrupt drug development through generous endowments in the scarce commodities of freedom, time and patience.

C-Suite Speaks Innovation

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Innovation Research and Development Strategies

‘System Thinking’ For Innovation In Digital Transformation

Digital transformation: it is the buzz phrase of the decade, and rightly so. We are living amidst a technology shift, a complete revolution of technology that in the next 10 to 15 years will change everything, in business as well as in our everyday lives. Peter Shone, chief technology officer at PAREXEL Informatics, shares his thoughts on how industry can be more proactive in clinical development using digital technologies.

Digital Health Innovation

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Casebia Counts On Collaboration In Its Climb To Leadership In Gene Therapy

Casebia Therapeutics, a three-year old start-up in the hotly contested gene therapy space, is the product of a remarkably relaxed joint venture between the German multinational giant Bayer and CRISPR Therapeutics, a leader in conducting the first clinical trial involving the CRISPR-Cas9 editing platform. 

C-Suite Speaks Leadership

Execs On The Move, March 2019

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

Luciano Rossetti, head of global research and development at Merck KGaA, believes the mid-sized pharma is well on its way to becoming a global immuno-oncology specialist. He discusses in-house innovation, the company’s recent IO alliance with GSK and the next wave of success that is beginning to swell across the cancer drug development community.

C-Suite Speaks Business Strategies

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?

Market Access Pharmacy Benefit Management

Innovations In Market Access: The Will, But Not The Way?

In this In Vivo executive roundtable, an informal working group of biopharma leaders in market access reviews the current state of play with regulators, patients and payers. Contacts with the first two stakeholders are clear-eyed and surprisingly productive, but the payer remains the tie that grinds – an inscrutable partner of necessity in moving complex, costly innovations toward acceptance in the marketplace.  

Market Access Pricing Strategies

Podcast: Medtech Pressure Points And Opportunities In 2019

Menacing clouds on the horizon, or opportunity for medtechs large and small in the evolving health care delivery ecosystems? Probably both, and a significant amount of risk, too, for those medtechs who push through the pain barrier to, in some cases, redefine their own roles. Helping patients understand the value being created will also be a major success factor for medtechs. Whatever the outcomes, these are exciting times, says ZS' Brian Chapman, in this future-gazing podcast with In Vivo.  

Medical Device Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals In Depth: February 2019

In a deal worth over $4bn, GlaxoSmithKline and Merck KGAA will develop M7824, which targets two immuno-suppressive pathways. Danaher paid $21.4bn for GE Healthcare's biopharma business. Biopharma funding was up while device financing decreased from the previous month.

Deals BioPharmaceutical

Scaling Up For First Product Launch: Seven Hazards To Avoid

As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for their first launch.

Market Intelligence Launches

Deals Shaping The Medical Industry, April 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2019.

Deals Financing